|
|
|
|
|
Trepanier, Lauren A
 Lauren A. Trepanier, DVM, PhD
Associate Professor
Research Area: Drug Hypersensitivity. HIV. Drug Detoxification. Cytochrome b5 Reductase. Genetic and biochemical variability in drug metabolism and its relationship to adverse drug reactions and drug toxicity. Arylamines, nitroso compound and hydroxylamines. Sulfonamide drug hypersensitivity in AIDS patients. Therapeutic drug monitoring for veterinary patients.
Home Dept: Medical Sciences, School of Veterinary Medicine
Affiliated Depts: Molecular and Environmental Toxicology
Address
4254 Veterinary Medicine Building
2015 Linden
Madison, WI 53706
Phone: 608/265-9022 - Email
Research
Dr. Trepanier's research area is genetically determined differences in drug metabolism and their effect on the individual risk of drug toxicity. The major focus of her laboratory is the effect of variability in drug reduction pathways (cytochrome b5 and its reductase, and antioxidant pathways) on arylamine carcinogenesis, and on the outcome of sulfonamide hypersensitivity reactions in dogs and humans (particularly immunocompromised patients).
Publications- Miller JL, Trepanier LA. Inhibition by atovaquone of CYP2C9-mediated sulfamethoxazole hydroxylamine formation. Eur J Clin Pharmacol 58:69-72, 2002.
- Trepanier LA, Danhof R, Toll J, Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with potentiated sulfonamides. J Vet Intern Med 17: 647-652, 2003.
- Trepanier LA, Yoder AR, Bajad S, Beckwith MD, Bellehumeur JL, Graziano FM. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole nitroso in HIV infection. J Acquir Immunodef Syndr 36: 1041-1050, 2004.
- Trepanier LA. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27: 129-138, 2004.
- Kurian JR, Bajad S, Miller JL, Chin N, Trepanier LA. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther 311:1171-8, 2004.
- Lavergne SN, Volkman EM, Maki JE, Yoder AR, Trepanier LA. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs. Toxicology 208: 63-72, 2005.
- Trepanier LA, Bajad SU, Kurian JR. Evaluation of the cytochrome b5 / cytochrome b5 reductase pathway Current Protocols in Toxicology 14.16.1-14.16.17, 2005.
- Saulter JY, Kurian JR, Trepanier LA, Tidwell RR, Bridges AS, Boykin DW, Stephens CE, Anbazhagan M, Hall JE. Unusual dehydroxylation of antimicrobial amidoxime prodrugs by cytochrome b5 and NADH cytochrome b5 reductase. Drug Metab Disp 33:1886-1893, 2005.
- Lavergne SN, Kurian JR, Bajad SU, Maki JE, Yoder AE, Guzinski MV, Graziano FM, Trepanier LA. Roles of endogenous ascorbate and glutathione in the cellular reduction and cytotoxicity of sulfamethoxazole-nitroso. Toxicology 222: 25-36, 2006.
- Lavergne SN, Danhof R, Volkman E, Trepanier LA. Association of
drug-serum protein adducts and anti-drug antibodies in dogs with
sulfonamide hypersensitivity: a naturally occurring model of
idiosyncratic drug toxicity Clin Exp Allergy 36: 907-15, 2006. - Kurian JR, Chin NA, Longlais BJ, Trepanier LA. Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. Chem Res Toxicol 19:1366-73, 2006.
- Kurian JR, Longlais BJ, Trepanier LA. Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity. Pharmacogenetics and Genomics (in press).
Check PubMed for other publications by Lauren Trepanier
|
|
